According to a recent LinkedIn post from Lyfegen, the company highlights growing market disruption from Most Favored Nation (MFN) pricing dynamics in global pharmaceuticals. The post cites recent examples, including Amgen’s withdrawal of cardiovascular drug Repatha from Denmark after reimbursement and Insmed Inc.’s pause of its EU and Japan launch of Brinsupri due to MFN-related uncertainty.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also references comments from Germany’s pharmaceutical industry association VFA, which reportedly sees companies postponing launches while assessing how potential U.S. pricing policy may use low reference-country prices as benchmarks. Lyfegen positions its 2025 Drug Contracting Trends Report as an analysis of these shifts and suggests manufacturers are reassessing launch sequencing, pricing, and market-access strategies.
For investors, the scenarios described imply heightened pricing risk, launch volatility, and potential revenue timing shifts for global drug makers exposed to MFN-style reference mechanisms. If companies delay or withdraw launches in lower-priced markets to protect U.S. pricing, this could alter geographic revenue mix, extend time-to-peak sales, and increase the strategic value of analytics and contracting platforms such as those marketed by Lyfegen.
The post further suggests that uncertainty around future U.S. policy could influence capital allocation decisions across pipelines, with later-stage assets in price-sensitive indications facing particular scrutiny. As market access complexity rises, firms that can optimize value-based contracts and cross-market pricing strategies may secure a competitive edge, potentially benefiting specialized consultancies and software providers active in this niche.